Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NTSR1 | P30989 | 6/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 3/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 2/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25146817 | 0.88 | KMT2A (0.54) | KMT2ANTSR1PPARDPPARAPPARG | |
| SCHEMBL23512372 | 0.85 | KMT2A (0.51) | KMT2ANTSR1PPARDPPARAPPARG | |
| SCHEMBL14947704 | 0.82 | NTSR1 (0.57) | KMT2ANTSR1L3MBTL1GLO1 | |
| SCHEMBL3194262 | 0.80 | SERPINE1 (0.57) | KMT2ANTSR1HTR6 | |
| SCHEMBL29420405 | 0.80 | KMT2A (1.00) | KMT2ANTSR1 | |
| SCHEMBL1598786 | 0.80 | KMT2A (1.00) | KMT2ANTSR1 | |
| SCHEMBL30103437 | 0.79 | KMT2A (0.62) | KMT2ANTSR1PPARDPPARAPPARG | |
| SCHEMBL4234811 | 0.79 | KMT2A (0.62) | KMT2ANTSR1PPARDPPARAPPARG | |
| Hydrochloric Acid SCHEMBL25303352 | 0.78 | KMT2A (0.96) | KMT2ANTSR1 | |
| SCHEMBL5537950 | 0.78 | KMT2A (0.60) | KMT2ANTSR1PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | BETA CAT PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123281-A1 | Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules | TBL2, TBL3, TBL1XR1 | KMT2A 4037/4885NTSR1 3572/4885L3MBTL1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.